Navarro-Compán, Victoria http://orcid.org/0000-0002-4527-852X
Baraliakos, Xenofon http://orcid.org/0000-0002-9475-9362
Magrey, Marina http://orcid.org/0000-0002-6520-5619
Östör, Andrew
Saffore, Christopher D.
Mittal, Manish
Song, In-Ho
Ganz, Fabiana
Stigler, Jayne
Deodhar, Atul http://orcid.org/0000-0002-2130-1246
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2
https://doi.org/10.1007/s40744-023-00550-4
POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.2699
POS0306 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2022-eular.2518
OP0016 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2022-eular.2534
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis
https://doi.org/10.1007/s40744-023-00536-2
POS1108 EFFICACY OF UPADACITINIB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN EARLY VERSUS ESTABLISHED DISEASE
https://doi.org/10.1136/annrheumdis-2023-eular.2123
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
https://doi.org/10.1136/ard-2022-222608
POS0685 MONITORING PHYSICAL ACTIVITY OF PATIENTS WITH ANKYLOSING SPONDYLITIS IN THE SELECT-AXIS 2 PHASE 3 TRIAL: BASELINE USAGE AND ADHERENCE RESULTS FROM A WEARABLE DEVICE STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.517
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
https://doi.org/10.1136/rmdopen-2022-002280
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
OP0061 DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2394
POS1111 TREATMENT WITH UPADACITINIB RESULTS IN THE INHIBITION OF A BROAD RANGE OF POTENTIALLY PATHOGENIC PATHWAYS IN NR-AXSPA AND BDMARD-IR AS PATIENTS: PROTEOMIC ANALYSIS FROM THE SELECT-AXIS 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.3708
AB0947 EFFECT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND INADEQUATE RESPONSE TO BIOLOGIC THERAPY
https://doi.org/10.1136/annrheumdis-2023-eular.3918
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
https://doi.org/10.1136/rmdopen-2021-002049
Funding for this research was provided by:
AbbVie
Article History
Received: 7 November 2022
Accepted: 25 January 2023
First Online: 23 February 2023